Navigation Links
Treatment of Bacterial Infection Paves the Way to Treat CF Infection

According to the researchers at the Harvard Medical School it is said that a resistant bacteria was found in the lungs of chronically infected cystic fibrosis (CF) patients. // Pseudomonas aeruginosa (PA) is the bacteria which secretes proteins that cause disease in the CF patients says Joseph Mougous, lead author of the study published in the June 9 issue of Science. ‘In the case of Pseudomonas aeruginosa, the host may be a cancer patient with a weakened immune system, a burn patient, or a person with cystic fibrosis (CF).’

Pseudomonas aeruginosa (PA), a pathogen that infects more than 80 percent of cystic fibrosis patients, is a leading cause of these patients' death. PA is difficult to treat because it is resistant to many drugs. ‘Since we know so little about what this bacterium is up to while it's engaged in these chronic infections, the discovery of this protein secretion system might lead to finding a new target for treatments,’ said Mougous, a research fellow in the Harvard Medical School (HMS) Department of Microbiology and Molecular Genetics. Researchers at Argonne National Laboratory (ANL) provided one of the clues that contributed to the HMS discovery.

Working through a number of pathogenic proteins, ANL protein crystallographer Marianne Cuff saw a bagel-shaped pore that might be involved in transferring toxins into cells. She deposited the structure of the protein, called Hcp1, into the Protein Data Bank, a resource used by biologists worldwide to find information about the proteins they are studying. While exploring the Protein Data Bank, Mougous, who was studying PA in the laboratory of department chair John Mekalanos, recognized that the amino acid sequence of Hcp1 in PA closely resembled that of Hcp1 in Vibrio cholerae. The Mekalanos lab had previously discovered that the Hcp1 protein of V. cholerae is released from the bacterium via a novel secretion pathway. Because Hcp1 proteins from both pathogens belong to the same protein family, Mougous wondered whether the Pseudomonas Hcp1 might also be secreted via this pathway. The Harvard and Argonne researchers quickly formed a collaboration and confirmed the hypothesis.

They then turned their attention to Hcp1 in cystic fibrosis patients to gain more insight in the role of Hcp1 during infection. Working with cystic fibrosis patients at Children's Hospital Boston, the HMS researchers sought and found Hcp1 in the sputum of patients with P. aeruginosa. They also found Hcp1 antibodies in the patients' blood – further evidence that Hcp1 plays a critical role in the infection. The human immune system creates antibodies to pathogens it is exposed to. ‘CF patients are particularly susceptible to PA,’ Mougous said. ‘The bacterium thrives in the excess mucus that accumulates in their lungs. Once a PA infection in a CF patient's lung has been established, these hardy bacteria are difficult or impossible to clear, which over many years eventually results in the death of the patient. Our paper provides evidence that the protein secretion system we discovered represents at least one way this bacterium could be promoting its own survival in the lungs of CF patients.’ ‘This finding provides a possible drug target to fight the infection in cystic fibrosis patients,’ added Andzrej Joachimiak, director of Argonne's Structural Biology Center and of the Midwest Center for Structural Genomics based at Argonne.

Source: Erekalert
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/24/2017)... ... August 24, 2017 , ... Lori ... the development and advances in Desensitization therapy to improve the outcomes of organ ... about his remarkable journey of his 25 years of research in developing therapies ...
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home ... have a condition that needs further monitoring such as surgery, stroke, heart attack ... stable, such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. ...
(Date:8/23/2017)... ... 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs and ... community organization for people with special needs. The group, the Special Needs Alliance for ... of New Jersey – but the first in the entire country! , SNAP was ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... ... Awards have announced the winners of the Best of the IBA Awards in The 2017 ... in the 2017 IBAs were not able to apply for the Best of the IBA ... awards won in the IBAs with a Gold Stevie win counting for three points, a ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017   Mostyn Law and Gulf Coast Regional Blood ... . The Mostyn Law family has had 3 ... is why Mostyn Law is partnering with Gulf Coast ... its appreciation. Blood supplies are running low. Gulf Coast ... hospital needs in August. That is why the blood center reached ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: